Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$74.43 - $92.22 $2.7 Million - $3.35 Million
-36,331 Reduced 45.95%
42,738 $3.52 Million
Q1 2024

May 15, 2024

SELL
$83.81 - $99.0 $29.5 Million - $34.9 Million
-352,274 Reduced 81.67%
79,069 $6.91 Million
Q4 2023

Feb 14, 2024

BUY
$76.22 - $98.51 $17 Million - $22 Million
223,656 Added 107.69%
431,343 $41.6 Million
Q3 2023

Nov 14, 2023

SELL
$85.07 - $94.48 $649,509 - $721,354
-7,635 Reduced 3.55%
207,687 $18.4 Million
Q2 2023

Aug 14, 2023

BUY
$86.68 - $100.3 $17.4 Million - $20.1 Million
200,309 Added 1334.24%
215,322 $18.7 Million
Q1 2023

May 15, 2023

SELL
$87.74 - $117.27 $51.4 Million - $68.6 Million
-585,259 Reduced 97.5%
15,013 $1.46 Million
Q4 2022

Feb 14, 2023

BUY
$80.93 - $108.63 $11.3 Million - $15.1 Million
139,313 Added 30.22%
600,272 $62.1 Million
Q3 2022

Nov 14, 2022

SELL
$82.16 - $96.94 $10.5 Million - $12.4 Million
-127,659 Reduced 21.69%
460,959 $39.1 Million
Q2 2022

Aug 15, 2022

BUY
$71.48 - $86.85 $15.9 Million - $19.3 Million
222,438 Added 60.75%
588,618 $48.8 Million
Q1 2022

May 16, 2022

SELL
$74.28 - $92.69 $19.6 Million - $24.4 Million
-263,254 Reduced 41.82%
366,180 $28.2 Million
Q4 2021

Feb 14, 2022

BUY
$71.72 - $91.47 $21 Million - $26.8 Million
293,449 Added 87.34%
629,434 $55.6 Million
Q3 2021

Nov 15, 2021

BUY
$74.77 - $85.47 $22.1 Million - $25.2 Million
295,034 Added 720.46%
335,985 $26 Million
Q2 2021

Aug 13, 2021

BUY
$75.51 - $84.79 $3.09 Million - $3.47 Million
40,951 New
40,951 $3.42 Million
Q1 2021

May 17, 2021

SELL
$74.73 - $90.69 $4.81 Million - $5.84 Million
-64,396 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$72.61 - $90.2 $16.8 Million - $20.8 Million
-231,129 Reduced 78.21%
64,396 $5.65 Million
Q3 2020

Nov 16, 2020

BUY
$71.87 - $131.03 $15.5 Million - $28.2 Million
215,264 Added 268.2%
295,525 $22.5 Million
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $5.49 Million - $8.57 Million
69,015 Added 613.68%
80,261 $9.9 Million
Q1 2020

May 15, 2020

SELL
$71.37 - $96.85 $19.2 Million - $26.1 Million
-269,525 Reduced 95.99%
11,246 $951,000
Q4 2019

Feb 14, 2020

BUY
$64.27 - $86.37 $16.4 Million - $22 Million
254,681 Added 976.16%
280,771 $23.7 Million
Q3 2019

Nov 14, 2019

SELL
$67.4 - $85.11 $17.3 Million - $21.8 Million
-256,022 Reduced 90.75%
26,090 $1.76 Million
Q2 2019

Aug 14, 2019

BUY
$80.35 - $93.9 $22.6 Million - $26.4 Million
281,636 Added 59167.23%
282,112 $24.2 Million
Q1 2019

May 14, 2019

SELL
$84.2 - $98.62 $2.62 Million - $3.07 Million
-31,097 Reduced 98.49%
476 $42,000
Q4 2018

Feb 14, 2019

BUY
$80.14 - $106.07 $1.75 Million - $2.31 Million
21,784 Added 222.54%
31,573 $2.69 Million
Q3 2018

Nov 14, 2018

BUY
$93.92 - $105.72 $592,541 - $666,987
6,309 Added 181.29%
9,789 $949,000
Q2 2018

Aug 14, 2018

SELL
$76.01 - $99.03 $359,451 - $468,312
-4,729 Reduced 57.61%
3,480 $328,000
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $218,408 - $260,475
2,812 Added 52.1%
8,209 $666,000
Q4 2017

Feb 14, 2018

BUY
$80.76 - $95.13 $435,861 - $513,416
5,397
5,397 $481,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Marshall Wace, LLP Portfolio

Follow Marshall Wace, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.